{"denoms":[{"counts":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"97"}],"units":"Participants"}],"groups":[{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"BG000","title":"NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"BG001","title":"NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.\n\nDurvalumab: Given IV\n\nTremelimumab: Given IV","id":"BG002","title":"NSCLC Arm C (Tremelimumab, Durvalumab)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.\n\nBeginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"BG003","title":"CRC Arm A Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14..\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"BG004","title":"CRC Arm B (Tremelimumab, Durvalumab, LD-RT)"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46.0","upperLimit":"88.0","value":"65.5"},{"groupId":"BG001","lowerLimit":"45.0","upperLimit":"77.0","value":"68.0"},{"groupId":"BG002","lowerLimit":"29.0","upperLimit":"77.0","value":"65.5"},{"groupId":"BG003","lowerLimit":"38","upperLimit":"79","value":"58"},{"groupId":"BG004","lowerLimit":"29","upperLimit":"77","value":"59"},{"groupId":"BG005","lowerLimit":"29.0","upperLimit":"88.0","value":"66.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"39"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"58"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"88"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"4"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"78"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"97"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"31"}],"title":"0 (Fully active)"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"64"}],"title":"1 (Restricted in strenuous activities)"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"}],"title":"2 (Restricted in work; capable of self care)"}]}],"description":"The Eastern Cooperative Oncology Group (ECOG) performance status (PS) scale measures a patient's functional status in relation to cancer. The scale describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability. Scoring is as follows: 0 - Fully active; 1 - Restricted in strenuous activity; 2 - Restricted in work activity, but ambulatory and capable of self-care; 3 - Capable of limited self-care; 4 - Completely disabled; 5 - Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status (PS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"75"}],"title":"Adenocarcinoma"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"9"}],"title":"Squamous"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"13"}],"title":"Not specified"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"58"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"39"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Previous Radiotherapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"4","value":"3"},{"groupId":"BG001","lowerLimit":"2","upperLimit":"3","value":"3"},{"groupId":"BG002","lowerLimit":"2","upperLimit":"4","value":"3"},{"groupId":"BG003","lowerLimit":"2","upperLimit":"7","value":"4"},{"groupId":"BG004","lowerLimit":"1","upperLimit":"7","value":"3"},{"groupId":"BG005","lowerLimit":"2","upperLimit":"4","value":"3"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Previous lines of therapy","unitOfMeasure":"Lines of therapy"}],"populationDescription":"Participants receiving at least one dose of protocol therapy."}